PPIDT00238
Drug Information
| Name | Triptorelin |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB06825 |
| Type | small molecule |
| Indication | Triptorelin is indicated for the palliative treatment of advanced prostate cancer. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Parenteral |
0.1 MG/ML
|
| Injection, powder, for solution | Intramuscular; Subcutaneous |
0.1 MG/ML
|
| Injection, powder, for suspension | Intramuscular |
3.75 mg
|
| Injection, powder, for suspension | Parenteral |
3.75 MG/2ML
|
| Injection, powder, for suspension, extended release | — |
11.25 MG/2ML
|
| Injection, powder, for suspension, extended release | — |
22.5 MG/2ML
|
| Solution | Subcutaneous |
0.1 mg / mL
|
| Injection | Parenteral |
0.1 mg
|
| Injection; solution | Subcutaneous |
|
| Injection, solution | Subcutaneous |
0.1 mg/mL
|
| Injection, powder, for suspension | Intramuscular |
375000 mg
|
| Powder | — |
3.75 mg
|
| Injection, powder, for solution | Intramuscular; Subcutaneous |
3.75 mg/syringe
|
| Injection, suspension, extended release | Intramuscular; Subcutaneous |
3.75 mg
|
| Capsule, extended release | Intramuscular; Subcutaneous |
4.12 mg
|
| Suspension | Subcutaneous |
3.75 mg
|
| Injection | Subcutaneous |
100 mcg/ml
|
| Injection, powder, for suspension | Intramuscular |
1125000 mg
|
| Injection, powder, for suspension | — |
|
| Injection, powder, for suspension, extended release | Intramuscular; Subcutaneous |
3.75 mg
|
| Injection, powder, for suspension | Intramuscular |
11.25 mg
|
| Injection, powder, for suspension, extended release | Intramuscular; Subcutaneous |
11.25 mg
|
| Injection, powder, for suspension, extended release | Intramuscular |
3.75 mg
|
| Injection, solution | — |
|
| Injection, solution | — |
0.1 MG/1ML
|
| Injection, solution | — |
0.1 mg/ml
|
| Solution | Subcutaneous |
0.09560 mg
|
| Solution | Subcutaneous |
95.6 mcg
|
| Injection, powder, for suspension, extended release | Intramuscular; Subcutaneous |
3.75 mg/ml
|
| Suspension | Other |
4.1200 mg
|
| Injection, powder, lyophilized, for solution | — |
11.25 mg
|
| Injection, powder, lyophilized, for solution | — |
22.5 mg
|
| Injection, powder, lyophilized, for solution | — |
3.75 mg
|
| Suspension | Parenteral |
3.750 MG
|
| Injection, powder, for suspension | Intramuscular |
22.5 mg
|
| Injection, powder, for suspension | Parenteral |
11.25 mg
|
| Injection, powder, for suspension | Parenteral |
22.5 mg
|
| Injection, powder, for suspension | Parenteral |
3.75 mg
|
| Injection, powder, lyophilized, for suspension | Intramuscular |
11.25 mg
|
| Injection, powder, lyophilized, for suspension | Intramuscular |
22.5 mg
|
| Injection, powder, lyophilized, for suspension | Intramuscular |
3.75 mg
|
| Injection, powder, for suspension, extended release | Intramuscular |
11.25 mg / vial
|
| Injection, powder, for suspension, extended release | Intramuscular |
22.5 mg / vial
|
| Injection, powder, for suspension, extended release | Intramuscular |
3.75 mg / vial
|
| Injection, powder, lyophilized, for suspension | Intramuscular |
11.25 mg/2mL
|
| Injection, powder, lyophilized, for suspension | Intramuscular |
22.5 mg/2mL
|
| Injection, powder, lyophilized, for suspension | Intramuscular |
3.75 mg/2mL
|
| Injection, powder, lyophilized, for suspension; kit | Intramuscular |
11.25 mg/2mL
|
| Injection, powder, lyophilized, for suspension; kit | Intramuscular |
3.75 mg/2mL
|
| Kit | Intramuscular |
11.25 mg/2mL
|
| Kit | Intramuscular |
22.5 mg/2mL
|
| Kit | Intramuscular |
3.75 mg/2mL
|
| Injection, powder, lyophilized, for suspension; kit | Intramuscular |
22.5 mg/2mL
|
| Injection, solution | Parenteral |
0.1 mg/ml
|
| Solution | Subcutaneous |
0.1 mg/1ml
|
| Injection, powder, for solution | Intramuscular; Subcutaneous |
3.75 mg/1vial
|
| Injection, powder, for solution | Intramuscular; Subcutaneous |
0.1 mg/1vial
|